Avanos Medical, Inc.
HealthcareNYSE:AVNS · New York Stock Exchange
-$0.02 today
Vol 0.31M · Avg 1.51M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-8.7%
avg -8.0%
ROIC
-6.6%
avg 1.6%
ROA
-6.3%
avg -5.2%
Analysis
ROA is currently the strongest return metric at -6.3% versus its period average of -5.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David C. Pacitti | Chief Executive Officer & Director | $2.47M | — | 60 | $0.00 | <0.01% |
Sigfrido Delgado | Senior Vice President of Operations | $897,819.00 | — | 49 | $55,741.00 | 0.12% |
Jason Pickett | Vice President of Corporate Finance & Treasurer | $871,118.00 | — | 54 | $0.00 | <0.01% |
Scott Galovan | Chief Financial Officer & Senior Vice President | $789,139.00 | — | 47 | $135,596.00 | 0.29% |
Scott Michael Galovan | Chief Financial Officer & Senior Vice President | $789,139.00 | — | 47 | $135,596.00 | 0.29% |
John Joseph Hurley | Principal Accounting Officer & Controller | — | — | — | $13,592.00 | 0.03% |
John S. Fischer | Vice President, Head of Legal & Secretary | — | — | 68 | $13,592.00 | 0.03% |
Jonathan Turner | Vice President and Chief Ethics & Compliance Officer | — | — | — | — | — |
Camille Chang Gilmore | SVP & Chief Human Resources Officer | — | — | — | — | — |
Jamie Handler | Vice President of Global Marketing | — | — | — | — | — |
Katrine Kubis | Vice President of Corporate Communications & Community Relations | — | — | — | — | — |
Siobhan Smyth | Vice President & Chief Information Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$659,300.00
Sells
4
$165,014.21
Net Sentiment
+$494,285.79
Net buying
Most Active
Holbrook Kerr
4 transactions
Analysis
Insiders reported 2 buys worth $659,300.00 and 4 sells worth $165,014.21 over the last 12 months. That adds up to net buying of $494,285.79. Holbrook Kerr was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -2.2% | -6.1% (12yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | -11.9% | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -2.2% over three years. Forward estimates point to Revenue at -6.1% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
CeriBell, Inc.
NASDAQ:CBLL
$700.80M
Bioventus Inc.
NASDAQ:BVS
$576.54M
Cytek Biosciences, Inc.
NASDAQ:CTKB
$511.40M
Varex Imaging Corporation
NASDAQ:VREX
$464.78M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Community Health Systems, Inc.
NYSE:CYH
$439.66M
Pacific Biosciences of California, Inc.
NASDAQ:PACB
$406.89M
ClearPoint Neuro, Inc.
NASDAQ:CLPT
$403.06M
Standard BioTools Inc.
NASDAQ:LAB
$346.53M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
Who manages AVNS?
Avanos Medical, Inc. (AVNS) lists 12 active executives. The top listed executive is David C. Pacitti, Chief Executive Officer & Director.
Are AVNS insiders buying or selling?
Recent insider activity shows net buying of $11.11M.
Explore More
Continue the stock analysis
Jump to another research area for this company.